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How much information about the benefits of medicines is included in patient 
leaflets in the European Union?  ? A survey. 
Abstract 
Introduction 
Patient information leaflets (PILs) are required with all licenced medicines throughout the European 
Union (EU) and they must include information about all side effects and their likelihood. This has led 
to criticism of a lack of balance, with little information included about potential benefits. Recent 
European Medicines Agency guidance proposed the inclusion of benefit information, and this study 
examined the current prevalence and type of such information in PILs in the EU. 
Methods 
A survey and content analysis of the English translation of PILs in the EU. Random quota sampling 
was used on the most frequently dispensed (n=50) and newly licenced medicines (n=50) in 2011/2. 
Leaflets were searched for benefit information meeting predefined criteria, and data synthesised 
and categorised into 10 categories. 
Results 
Eighty-five (85%) leaflets described how the medicine works, with 45 providing information about 
the rationale for treatment (more commonly for newly licensed (32/50) than most commonly 
dispensed medicines (13/50; p<0.001). Nearly half (47) did not describe whether the medicine was 
curative, symptomatic or preventative. The terms used to communicate uncertainty were imprecise 
(such as  ?ŵĂǇŚĞůƉ ?). None communicated numerical benefit information. 
Conclusion 
Current PILs do not appropriately communicate information about benefit. At the basic level, around 
a half did not include information about treatment rationale or whether the treatment was to treat 
symptoms, curative or preventative. However, for true informed decision making, patients need 
quantitative information about benefits and none of the leaflets provided this.  
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1. Introduction 
In order for patients to make informed decisions about their medicines they need good quality 
information about the likelihood both of harms and benefits of treatments (Raynor et al 2007). 
Patient information leaflets (PILs), written by the manufacturer according to strict guidelines, are 
required to be supplied with all licenced medicines throughout the European Union (EU). The 
guidelines require that PILs should include information about all side-effects of a medicine and their 
likelihood (1). This information usually takes the form of both a verbal descriptor and a probability to 
form a combined risk expression, such as Common: may affect up to 1 in 10 patients. 
A recent survey showed that all sampled EU medicine leaflets in 2013 provided such numerical 
indicators of the risk of side effects, with most using the format recommended by the European 
Commission (2). 
A common criticism of PILs is that they are too negative and focus only on the side effects of the 
treatment (3). Alongside this, there is evidence that patients desire information about the benefits 
of their treatments in order to help them make informed decisions (4). There is also increasing 
evidence to support the notion that patients overestimate the benefits and underestimate the 
harms of their treatments, particularly in the absence of numerical information (5).   If patients are 
unable to form accurate representations of the risk and benefits of their treatments this has an  
impact upon their ability to make truly informed decisions. 
EU regulatory bodies have become increasingly interested in including additional information about 
the potential benefits of medicines in PILs  (6-8). However, currently little is known about the extent 
to which PILs include benefit information and how this information is presented. Such information 
could range from basic information about the way the medicine works, through to numerical 
information about how likely are patients to benefit from the treatment. The aim of this study was 
to determine the extent to which information about the benefits of treatments was included in a 
sample of PILs for medicines currently provided in the EU, and to categorise the different types of 
benefit information provided. 
2. Methods 
This was ĂƐƵƌǀĞǇĂŶĚĐŽŶƚĞŶƚĂŶĂůǇƐŝƐŽĨƚŚĞ 威༁ḁ瘁ḁ⠁?ƚŝŶĨŽƌŵĂƚŝŽŶ ?contained in medicine patient 
information leaflets. A quota sample was taken of the English version of 100 PILs currently available 
in the EU, with a desire to include both established and new medicines from a range of 
manufacturers (who write the leaflets). Hence the leaflets were obtained from two representative 
groups of leaflet types: 
1] For the top 50 dispensed medicines: identified from national prescription cost analysis data which 
provides details of items dispensed in the community ( 
2011) (9), and reflecting the most common medicines that patients, and therefore the most 
common leaflets that people, receive. The list of top 50 dispensed medicines was randomised using 
a random list generator (www.random.org). The top half of the list (n=25) was allocated a leaflet 
from a branded medicine and the bottom half (n=25) a leaflet from a generic medicine, to determine 
if any differences were evident.  
2] For the  ? ?ŶĞǁůǇůŝĐĞŶĐĞĚŵĞĚŝĐŝŶĞƐ ?ĨƌŽŵƚŚĞ 娀BůĂĐŬdƌŝĂŶŐůĞůŝƐƚ ?: identified from the Medicines 
and Healthcare Products Regulatory Agency (MHRA; the UK medicines regulator) list ŽĨ ?Drugs under 
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intensive surveillance (2012) 弃? by the date their marketing authorisation was granted. (This list is 
also known as the  ?Black triangle ? list and referred to as such in this paper).This group of medicines 
are newly licensed and as such provide a comparison to the older, commonly dispensed medicines. 
The rationale for including this group was to see whether the manufacturers of PILs were responding 
to regulatory moves towards the inclusion of benefit information.  
Products such as vaccines, where a patient might not routinely receive a PIL were excluded, as were 
medicines that were new combinations, formulations, or routes of administration of existing 
medicines, or older medicines for which a new indication had been licensed. These medicines were 
excluded as they are not necessarily new treatments and might have existing PILs. Consequently it 
might mean that the patient information is older and changes relating to recent regulatory moves 
towards the inclusion of benefit information might be more difficult to identify. 
The total sample therefore contained 75% branded leaflets (50% from the Black Triangle List and 
25% from the top 50 dispensed group) and 25% generic leaflets (from the 50 top dispensed list). 
There was no overlap between the two lists (Figure 1). 
Obtaining the leaflets. 
The leaflets were accessed from the Electronic Medicines Compendium (eMC; 
www.medicines.org.uk) between 7th January and 20th February 2013. For branded medicines the 
British National Formulary (www.bnf.org.uk) was used to identify a single listed manufacturer. 
Where more than one manufacturer was listed, one was selected using a random number generator. 
Generic leaflets were chosen at random from the eMC; a random list generator was applied to the 
list of manufacturers and the leaflet that was randomly listed first chosen. For the next random 
selection, if it included a manufacturer previously used, this name was excluded in order to ensure a 
range of manufacturers were included.  In instances where only one manufacture was available this 
PIL was included regardless of previous selection. Once a manufacturer had a PIL included in the 
sample, that manufacturer was not included again unless it was the only manufacturer of a 
medicine. This ensured a range of manufacturers were included in the sample. 
Categorisation of benefit information  
There is no agreed existing categorisation of the types of benefit information for medicines. 
Therefore the benefit information criteria used for this analysis were derived from two sources: 
x Report of the European Medicines Agency on patient and professional expectations of 
information on the risk and benefits of medicines (7). 
x Guidance from the MHRA on patient information about medicines (6).  
To create a workable set of criteria to use as a framework for the analysis of the patient information 
leaflets, a content analysis and synthesis of the benefit information described by the two reports 
was undertaken. The documents were searched for definitions of benefit information and organised 
into 10 categories based on the words and numerical expressions used (Figure 2).  
Data extraction and quality assurance 
The information was extracted and entered into a database on which was recorded the frequency 
and type of information contained in the PILs. The lead researcher (RD) undertook the data 
extraction, and a random 10% check for accuracy was undertaken by another member of the 
research team (TR). The 10% check for accuracy was split into 2 X 5% checks. The first 5% check 
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revealed a small amount of missing data (in particular relating to identifying terms associated with 
conveying uncertainty). As a result RD rechecked the remaining data for any missing data. The final 
5% check was consistent, with both reviewers identifying the same data for each criterion. 
Statistical analysis  
Data were categorical and the following tests were applied: 
x Chi-square test 
x Fisher ?s exact test  ? used when the assumptions of the chi-spared test were violated (when 
cells had an expected count of less than 5). 
The Statistical Package for the Social Sciences (SPSS) version 19 was used to perform the analysis 
(10).  
3. Results 
One hundred PILs were obtained, with at least one leaflet from 59 different manufacturers. Table 1 
shows the total number of benefit criteria met according to leaflet type. The findings are listed 
below under each criterion  ? differences between generic and branded and new versus commonly 
dispensed were not statistically significant unless stated. 
Criteria 1 & 2: Does the leaflet describe what the medicine is for and does it describe how the 
medicine works? 
All of the leaflets (n=100) described what the medicine was used for, and 85 described how it 
worked.  
Criterion 3: Does the leaflet describe the rationale for why  the medicine is being taken? 
45 leaflets provided information about the rationale for treatment. Significantly more newly licensed 
medicines provided additional information about the rationale for treatment when compared to 
medicines which are commonly dispensed (n=32 compared to n=13, p<0.001). A post hoc analysis 
identified 4 different categories of rationale information (see figure 3). 
Criterion  ? ?ŽĞƐƚŚĞůĞĂĨůĞƚĚĞƐĐƌŝďĞǁŚĂƚǁŝůůŚĂƉƉĞŶŝĨǇŽƵĚŽŶ 嬁?ƚĂŬĞƚŚĞŵĞĚŝĐŝŶĞ ? 
22 leaflets described what could happen if the patient did not take the medicine (including stopping 
taking after initially starting to take): 
x 17 about the impact of not taking the medicine on the condition 
x 3 reported the impact on symptoms 
x 1 provided information on withdrawal 
x 1 described the impact of stopping on HIV resistance.  
 
17 of the leaflets explicitly described the impact of not taking the medicine, for example:  
 ?ŽŶŽƚƐƚŽƉƚĂŬŝŶŐƚŚŝƐŵĞĚŝĐŝŶĞĂƐǇŽƵƌŚĞĂƌƚƉƌŽďůĞŵŵĂǇŐĞƚǁŽƌƐĞ 堀 dĂůŬƚŽǇŽƵƌĚŽĐƚŽƌŝĨ
ǇŽƵǁĂŶƚƚŽƐƚŽƉ ?(Digoxin, top 50 dispensed, branded  ? Lanoxin). 
Three included some information about what might happen if the patient did not take the medicine, 
but it was imprecise, without reference to specific impact on conditions or symptoms. For example: 
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 ?/ĨǇŽƵƐƚŽƉƚĂŬŝŶŐůĂĐƚƵůŽƐĞƚŚĞĚĞƐŝƌĞĚĞĨĨĞĐƚƐŽĨƚŚĞŵĞĚŝĐŝŶĞŵĂǇŶŽƚďĞĂĐŚŝĞǀĞĚ ?
(Lactulose, top 50 dispensed, generic). 
Criterion 5: Does the leaflet describe whether the medicine will cure or alleviate the symptoms or 
is preventative? 
19 leaflets met this criterion, the majority of which were for symptom control medicines (n=13) and 
the remainder were preventative (n=6). Most of these statements (n=11) were explicit about 
whether symptomatic or preventative. For example: 
 ?[This medicine] is used to help relieve the symptoms of mild, moderate and severe asthma, 
other chest illnesses and to avoid asthma symptoms brought on ďǇĞǆĞƌĐŝƐĞŽƌŽƚŚĞƌ 威?ƌŝŐŐĞƌƐ 嬃堀 
Pulvinal must be used for the relief of your asthma symptoms only. You may have other 
ŵĞĚŝĐŝŶĞƐǁŚŝĐŚǇŽƵƚĂŬĞƌĞŐƵůĂƌůǇƚŽƉƌĞǀĞŶƚƚŚĞƐǇŵƉƚŽŵƐŽĨǇŽƵƌĂƐƚŚŵĂ ? ?(Salbutamol, 
top 50 dispensed, branded - Pulvinal) 
Eight leaflets were more implicit about the nature of the treatment, for example: 
 ?ǇďůŽĐŬŝŶŐƚŚĞĂĐƚŝǀŝƚǇŽĨ/>-1 beta, canakinumab leads to an improvement in these 
ƐǇŵƉƚŽŵƐ 堃?  (Canakinumab, black triangle, branded - Ilaris) 
Criterion 6: Is the duration of treatment described as short term or long term?  
53% of the leaflets described treatment duration, and this was more common in the black triangle 
group (n=33) than the most frequently dispensed group (n=20) (p= 0.069). In all, 23 of the 53 leaflets 
described a timescale for treatment. Sometimes this was described only as long-term or short-term 
treatment, for example: 
  ?Treatment with Cardicor is usually long-term. Cardicor is used to treat stable chronic heart 
ĨĂŝůƵƌĞ 堃? (Perindopril, top 50 dispensed, branded - Cardicor) 
Other leaflets specified a period of time, for example: 
 ?/ƚǁŝůůďĞŐŝǀĞŶƚŽǇŽƵƚǁŝĐĞĂǁĞĞŬ 縁?ƚůĞĂƐƚƚŚƌĞĞĚĂǇƐĂƉĂƌƚ ?ĨŽƌƚŚĞĨŝƌƐƚ ? ?ǁĞĞŬƐ 唀 ƚŚĞŶ
ŽŶĐĞĂǁĞĞŬĨŽƌ ? ?ŵŽƌĞǁĞĞŬƐ ? ? (Mifamurtide, black triangle, branded - Mepact) 
Thirteen leaflets said that treatment should continue as long as the doctor recommends, with no 
specific timescale, However, some of these provided a helpful explanation for this uncertainty, for 
example: 
 帀There is no time limit laid down as a general rule for treatment with Levact. Duration of 
ƚƌĞĂƚŵĞŶƚĚĞƉĞŶĚƐƵƉŽŶĚŝƐĞĂƐĞĂŶĚƌĞƐƉŽŶƐĞƚŽƚƌĞĂƚŵĞŶƚ 堃? (Bendamustine, black triangle, 
branded - Levact) 
Seventeen further leaflets described some information about treatment length, but were not explicit 
or were unclear in their description of the duration. 
A total of 47 leaflets did not describe the duration of treatment, nor recommend that patients seek 
advice about duration. This was more common in the top 50 dispensed category, where 30 leaflets 
provided no information on the duration of treatment compared to 17 in the black triangle group.  
Criterion 7: Does the leaflet convey any uncertainty associated with the treatment? 
A total of 37 leaflets (37%) presented information that conveyed uncertainty in some way. These 
were categorised into the following groups, post hoc:  
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 [1] No uncertainty conveyed. This was the majority (n=63), where the leaflets tended to include 
information about the effects of the medicine, for example: 
Arzerra is used to treat chronic lymphocytic leukaemia (CLL) (Ofatumumab  ? black triangle, 
branded  ? Arzerra) 
The remainder (n=37) used a mixture of terms to convey uncertainty and were categorised into the 
following groups: 
[2] Uncertainty about the impact of the treatment on the condition (associated with the effectiveness 
of the treatment).Two different methods of conveying such uncertainty were noted. Several used 
words to qualify treatment effectiveness, ƐƵĐŚĂƐ 威?ĞůƉƐ 嬃?ŽƚŚĞƌƐƵƐĞĚŵŽĚĂůĂƵǆŝůŝĂƌǇǀĞƌďƐ 唀 ǁŚŝĐŚ
are verbs which help to indicate modality or likelihood, sƵĐŚĂƐ ?ŵĂǇ 嬀 (11).  
2a: Implies uncertainty using the ƚĞƌŵ 威威ḁ?Ɖ/Ɛ ? (n=2 ? 缀 Žƌ 威ခ紁?ƚƌŝďƵƚĞƐƚŽ 嬀  ?Ŷс ? ? Examples 
include  威?ĞůƉƐůŽǁĞƌ ?,  ?helps prevent 嬃唀  威?ĞůƉƐƉƌŽƚĞĐƚ 嬀 ĂŶĚ 威?ontributes to lowering ? n=1 
2b: Implies uncertainty using the auxiliary verbƐ 威甁ȁ윃? 唀  威ခ?Ŷ 嬀 ĂŶĚ 威?ŚŽƵůĚ ? (n=14). Examples 
include  
o May treat n=2  
o May reduce n=2 
o May prevent / help control / relieve; all n=1 
o Should help / have an improvement; both n=1 
o Can reduce n=2  
o Can help / help relieve; both n=1 
o Can raise n=1 
dŚĞƵƐĞŽĨƚŚĞƐĞƚĞƌŵƐŝŶĂĚĚŝƚŝŽŶƚŽ 威威ḁ?Ɖ 嬀 ƐƵĐŚĂƐ ?ŵĂǇŚĞůƉ 嬀 ĂƉƉĞĂƌƐƚŽĂĚĚĨƵƌƚŚĞƌ
uncertainty. 
[3] Uncertainty associated with the likelihood of developing an illness. Some leaflets referred to the 
risk or chance of developing an illness. TŚĞƐĞůĞĂĨůĞƚƐƌĞĨĞƌƌĞĚƚŽƚƌĞĂƚŵĞŶƚƐ 威谁ḁ?ƵĐŝŶŐƚŚĞƌŝƐŬŽƌ
ĐŚĂŶĐĞ 嬀 ŽĨƚŚĂƚillness. There appeared to be 2 levels of uncertainty: 
 ?Ă ?/ŵƉůŝĞƐƵŶĐĞƌƚĂŝŶƚǇƵƐŝŶŐƚŚĞƚĞƌŵƐ ?ƌŝƐŬ ?Žƌ 威ခ?ĂŶĐĞ ? (n=10).The treatment  ?reduces the 
risk ? (n=8)  ?reduces the chance ? of condition (n=2) 
 ?ď ?/ŵƉůŝĞƐƵŶĐĞƌƚĂŝŶƚǇƵƐŝŶŐƚŚĞƚĞƌŵƐ ?ƌŝƐŬ ?Žƌ 威ခ?ĂŶĐĞ 嬀 ĂŶĚƵƐĞƐĂŶĂƵǆŝůŝĂƌǇǀĞƌď:  ?may 
reduce the risk/chance ? of a condition. (n=5);  威?an reduce the risk ? n=3,  ?may reduce the risk ? 
n=1,  ?will increase your chances ? n=1) 
Criteria 8 and 9: Numerical presentations of benefit 
None of the leaflets sampled included any numerical format of benefit information, i.e. information 
that  illustrates the proportion of patients who will benefit and/or the extent of the benefit on the 
symptoms of the condition, or information that presents any mean benefits of the medicine on a 
particular measure, for example blood pressure. 
4. Discussion 
This study shows that benefit information is variably communicated in PILs, with a large majority 
providing information about how the medicine works and just less than half giving additional 
rationale about the treatment. Uncertainty about the likelihood of benefit was generally only 
ŝŵƉůŝĐŝƚ 唀 ǁŝƚŚƵƐĞŽĨƚĞƌŵƐůŝŬĞ ?ŵĂǇ 嬀 ĂŶĚ 威威ḁ?ƉƐ 嬃?ďƵƚthe actual likelihood of benefit was not included 
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in any leaflet, neither textually nor numerically. This is despite information being routinely presented 
in PILs about the likelihood of harm through side effects.  
The information about the rationale for treatment was most commonly related to the illness, with 
newly licenced medicines more likely to communicate such information. Patients desire information 
which is set in context of their illness and this additional information can have a positive impact on 
ƉĞŽƉůĞ 嬁?ũƵĚŐĞŵĞŶƚƐ about the risks and benefits of their medicines (12-14) .This increase may 
reflect moves in recent years to balance what is perceived as negative information about side effects 
(15). This includes recent changes to the EU template for PILs (8), which now specifies that  威ခ?ĞĂƌĂŶĚ
ĐŽŶĚĞŶƐĞĚ ?information about the benefits of medicines can be included. However their suggested 
sub-heading ( ?,ŽǁyǁŽƌŬƐ 嬃缀 ĂŶĚƚŚĞĞǆĂŵƉůĞƐŐŝǀĞŶ ?ƐŚŽǁƚŚĂƚƚŚĞƌecommendation does not 
extend to numerical information about benefit likelihood and more about what the medicine does in 
the body. 
The sample of 100 leaflets allowed us to obtain variation in leaflet type and manufacturer, and 
facilitate a historic comparison of the frequency and type of benefit information. The criteria were 
developed from two regulatory sources and it is possible that the consideration of additional sources 
of benefit information might have led to the development of different criteria to define benefit 
information. However, it is unlikely that this would affect the frequency of numerical benefit 
information observed in patient information leaflets.  
Fundamental information for patient understanding of the medicine they are being expected to take 
is whether it is intended to cure the condition, alleviate symptoms or be preventative. Nearly half of 
leaflets did not explicitly communicate this. This is particularly worrying for those medicines intended 
to be taken indefinitely  ? an informed decision about whether to start taking such a medicine cannot 
be made without knowledge of this. Related to this, only a small proportion of leaflets provided 
detailed information about the duration of treatment of the medicine andsome of those that did 
used implicit terms which were unclear or non-specific. In slightly less than half of the leaflets there 
was no information about how long the treatment should be used. Again this is fundamental 
information for the patient if are they being expected to take the medicine for a few weeks or 
months, or for the rest of their lives? 
It was apparent that the majority of leaflets either did not convey the uncertainty associated with 
treatments, or conveyed uncertainty in a way that was largely inadequate or unclear. For example, 
ƚŚĞƵƐĞŽĨƚŚĞƚĞƌŵ 威威ḁ?ƉƐ 嬃?which appears to be used to convey uncertainty about the action of a 
treatment, can be confusing and seems to imply that the treatment works, but only in a contributory 
sense. It could be misconstrued as conveying that the treatment is effective, but only in conjunction 
with other treatments, when this is not necessarily the case.  
The use of auxiliary ǀĞƌďƐƐƵĐŚĂƐ 威ခȁ瘃嬀 Žƌ ?ŵĂǇ 嬀 ǁĞƌĞĂůƐŽƵƐĞĚŝŶƐŽŵĞůĞĂĨůĞƚƐ 堀 dŚŝƐƚĞchnique 
conveys uncertainty more clearly ƚŚĂŶƵƐŝŶŐ 威威ḁ?ƉƐ 嬀 ĂůŽŶĞ. However it is still ambiguous because it is 
unclear how much the treatment will help or reduce the risk of a condition. There is also some 
redundancy with the use of auxiliary verbs (such as may or can) when combined with terms such as 
 威谁?ƐŬ 嬀 Žƌ 威ခ威ȁ?ĐĞ ?, which already suggest uncertainty. This might lead to misunderstanding about the 
potential effectiveness of the medicine. Further research into the linguistics of communicating 
uncertainty in PILs could determine more effective terminology. 
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There was a slight tendency for 'black triangle' leaflets to include more benefit information than the 
top 50 dispensed leaflets on most, but not all, criteria. For two criteria the differences were 
statistically significant. These were duration of treatment (criterion 3) and whether the leaflet 
described the rationale of the treatment (criterion 6). It is possible that this increased performance 
relates to the more complex nature of some of the newly licenced treatments, some of which were 
for use in treatments such as chemotherapy regimens. This might also reflect a trend for newer, 
more recently authorised, leaflets to produce better quality information in line with some of the 
recent recommendations about improvements to the communication of medicines information.  (16, 
17) This increased inclusion of benefit information might also reflect a better availability and quality 
of effectiveness data as a result of undertaking of bigger and better designed trials over recent years.  
There was variation amongst the type and frequency of information included in the different leaflets. 
It is apparent that some providers of medicines information include more information about the 
benefits of a treatment than others. The use of terminology between the leaflets also varies. This has 
a potential impact on the reader receiving information about their medicines that varies from 
ƉƌŽĚƵĐƚƚŽƉƌŽĚƵĐƚĂŶĚŝƐŝŶĐŽŶƐŝƐƚĞŶƚ 堀 dŚĞŝŵƉĂĐƚŽĨƚŚŝƐƵƉŽŶĂƉĂƚŝĞŶƚ 嬁?ŬŶŽǁůĞĚŐĞĂŶĚ
understanding about their medicines is not known.
 
It is surprising that none of the leaflets conveyed benefit information in numerical terms. For 
patients to make informed decisions about their treatments it could be argued that they should be 
provided with information which is comparable with the presentation of information about the risk 
of harm.  There is increasing evidence that patients underestimate the risk of harm and 
overestimate the potential for benefit of their treatments which has implications for informed 
decision-making (4, 5, 18).  Patients desire information about the benefits of their treatments in 
order to counterbalance the impact of what is perceived to be negative risk information (4, 13, 14, 
19). The inclusion of textual benefit information has been shown to partly address this imbalance, 
however the impact of providing numeric benefit information is more complex (19). There is 
evidence to support the idea that the risks and benefits of treatments are better understood when 
presented in a numerical format (20, 21) although it is apparent that this is not without impact with 
patients reporting emotional responses, such as anxiety and unease,  about the inclusion of 
numerical benefit information in patient information leaflets (4, 18).  While patients report a 
preference for textual benefit information, it is apparent that the provision of numeric information 
can encourage more accurate interpretations of risks and benefits (21, 22).  The provision of well-
written benefit information in this context would be an appropriate accompaniment to the 
numerical frequency of side-effects already presented in PILs (23, 24). 
Policy makers should work towards standardising the definition of benefit information and provide 
regulated evidence-based guidelines on the type of information that should be provided in a PIL. 
While it is apparent that the provision of numeric benefit information is a complex process, the 
producers and regulators of medicines information need to consider how this type of information 
can be best incorporated into a PIL. The information provided must not be promotional but should 
aim to support the patient with their decision-making (16).  
 
Conclusion 
9 
This study has shown that the majority of leaflets in the UK do not contain clear or adequate 
information about the potential benefits of medicines. Leaflets do not consistently provide simple 
benefit information such as the rationale for treatment, the duration of treatment or whether the 
treatment is intended to be preventative, curative or symptomatic.  Uncertainty about treatment 
outcome is largely inadequately communicated, with leaflets using ambiguous terms that do not 
describe either the proportion of patients who are likely to benefit from the treatment, or the 
magnitude of benefit. There is a duty to attempt to inform patients regardless of whether or not the 
information being communicated is complex (24). It has been suggested that the package leaflet is an 
excellent place to communicate information about the benefits of medicines as it is something that is 
regulated and should be provided with all medicines (25). The manufacturers and regulators of 
medicines information need to address the lack of usable and comprehensive information about 
ŵĞĚŝĐŝŶĞƐ 嬀 ďĞŶĞĨŝƚƐŝŶ PILs. 
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Table 1: Benefit criteria met (including statistical difference between leaflets for top 50 dispensed medicines and Black Triangle medicines). 
 
Criteria 
 
Total 
criteria 
met 
n=100 
Top50 dispensed n (%) 50 Black Triangle n (%) Chi-square statistic, 
probability (p) value. 
(df=1 for all 
comparisons) 
Generic n=25 Branded n=25 
1: Does it describe what the medicine is used for? 100  25 (100%) 25 (100%) 50 (100%) - 
2: Does it describe how the medicine works? 85  21 (84%) 21 (84%) 43 (86%) .078 (p=0.779) 
3: Does the leaflet describe the rationale for taking 
the medicine? 
45  5 (20%) 8 (32%) 32 (64%) 14.586 (p<0.001) 
4: Does the leaflet describe what will happen if you 
ĚŽŶ 嬁騀 ƚĂŬĞƚŚĞŵĞĚŝĐŝŶĞ ? 
22  7 (28%) 5 (20%) 10 (20%) .233 (p=0.629) 
5: Does the leaflet describe whether the medicine 
will cure or alleviate symptoms or is preventative? 
19  5 (20%) 4 (16%) 10 (20%) .065 (p=0.799) 
6: Is the duration of the treatment described as 
either short term or long term? 
53  8 (32%) 12 (48%) 33 (66%) 3.305 (p=0.069) 
7: Does the leaflet convey any uncertainty 
associated with the treatment? 
37  10 (40%) 10 (40%) 17 (34%) .386 (p=0.534) 
8: Does the leaflet illustrate the likely proportion of 
patients who will benefit and the extent of the 
benefit on the symptoms of the condition? 
0 0 0 0 
 
- 
9: Does the leaflet present any mean benefits of the 
medicine on a particular measure? 
0 0 0 0 - 
